Tom 18, Nr 1-2 (2016)
Prace poglądowe
Opublikowany online: 2017-01-27
Wyświetlenia strony
764
Wyświetlenia/pobrania artykułu
1435
Nowe doustne antykoagulanty w leczeniu żylnej choroby zakrzepowo-zatorowej u pacjentów w podeszłym wieku na przykładzie rywaroksabanu
Chirurgia Polska 2016;18(1-2):9-15.
Streszczenie
Nowe doustne leki przeciwzakrzepowe od kilku lat zastępują tradycyjne antykoagulanty, będące antagonistami witaminy K w wielu dotychczasowych wskazaniach. Populacją, która wymaga często terapii przeciwzakrzepowej są pacjenci w podeszłym wieku. Artykuł podsumowuje korzyści i zagrożenia tej terapii (krwawienia, kumulacja leku u chorych z niewydolnością nerek) u chorych powyżej 75. roku życia. Artykuł podsumowuje dane dostępne z zakończonych badań klinicznych i rejestrów, mogące wspomagać lekarza w prowadzeniu terapii przeciwzakrzepowej u pacjenta w podeszłym wieku.
Słowa kluczowe: doustne antykoagulantyzator tętnicy płucnejzakrzepica żył głębokichstarszy pacjent
Referencje
- Zarraga IG, Kron J. Oral anticoagulation in elderly adults with atrial fibrillation: integrating new options with old concepts. J Am Geriatr Soc. 2013; 61(1): 143–150.
- Ageno W, Gallus A, Wittkowsky A, et al. Oral Anticoagulant Therapy. Chest. 2012; 141(2).
- Kearon C, Akl E, Ornelas J, et al. Antithrombotic Therapy for VTE Disease. Chest. 2016; 149(2): 315–352.
- Kearon C, Akl E, Comerota A, et al. Antithrombotic Therapy for VTE Disease. Chest. 2012; 141(2).
- Spyropoulos AC, Merli G. Management of venous thromboembolism in the elderly. Drugs Aging. 2006; 23(8): 651–671.
- Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost. 2010; 8(10): 2105–2112.
- Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22(8): 983–988.
- Deedwania PC. New oral anticoagulants in elderly patients with atrial fibrillation. Am J Med. 2013; 126(4): 289–296.
- Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care. 2009; 32(2): 287–294.
- Jacobs JM, Stessman J. New anticoagulant drugs among elderly patients is caution necessary?: Comment on "The use of dabigatran in elderly patients". Arch Intern Med. 2011; 171(14): 1287–1288.
- Robert-Ebadi H, Le Gal G, Righini M. Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging. 2009; 4: 165–177.
- Sardar P, Chatterjee S, Chaudhari S, et al. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc. 2014; 62(5): 857–864.
- Prins MH, Lensing AW, Bauersachs R, et al. EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013; 11(1): 21.
- Ageno W, Mantovani LG, Haas S, et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol. 2016; 3(1): e12–e21.
- Davidson BL, Verheijen S, Lensing AWA, et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med. 2014; 174(6): 947–953.
- Bauersachs R, Berkowitz SD, Brenner B, et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26): 2499–2510.
- Büller HR, Prins MH, Lensin AWA, et al. EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366(14): 1287–1297.
- Bauersachs RM, Lensing AWa, Prins MH, et al. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J. 2014; 12: 25.
- Norwood DA, Parke CK, Rappa LR. A Comprehensive Review of Potential Warfarin-Fruit Interactions. J Pharm Pract. 2015; 28(6): 561–571.
- Griffiths AP, Beddall A, Pegler S. Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin. J R Soc Promot Health. 2008; 128(6): 324–326.
- Jepson R, Craig J, Williams G, et al. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2000; 10(2): CD001321–1396.
- Laliberté F, Bookhart BK, Nelson WW, et al. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient. 2013; 6(3): 213–224.
- Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013; 34(27): 2094–2106.
- Sié P, Samama C, Godier A, et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis. Archives of Cardiovascular Diseases. 2011; 104(12): 669–676.
- Crowther MA, Warkentin TE. Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost. 2009; 7 Suppl 1: 107–110.
- Spyropoulos AC, Al-Badri A, Sherwood MW, et al. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012; 120(15): 2954–2962.
- Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011; 342: d124.
- Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004; 141(10): 745–752.
- Patel M, Mahaffey K, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011; 365(10): 883–891.
- Granger C, Alexander J, McMurray J, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011; 365(11): 981–992.
- Connolly S, Ezekowitz M, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009; 361(12): 1139–1151.
- Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med. 2011; 171(14): 1285–1286.
- Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother. 2012; 46(4): e10.
- Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012; 366(9): 864–866.
- Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014; 130(2): 138–146.
- Halvorsen S, Wallentin L, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2013; 61(10): E315.
- Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008; 47(5): 285–295.
- Flack KF, Desai J, Kolb JM, et al. Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation. Clin Gastroenterol Hepatol. 2017; 15(5): 682–690.
- Lip GYH, Larsen TB, Skjøth F, et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012; 60(8): 738–746.
